Safety and Efficacy Assessment of Autologous Bone-marrow Derived Adult Mesenchymal Stem Cell Therapy in Patients With Anoxic(or Hypoxic) Brain Injury Pilot Trial

Inclusion Criteria: * Patients older than 14 days after the index event occurs in an oxygen-free brain injury patients * Severe disability or moderate due to anoxic brain injury * 18 years to 75 years * Patients was 7 points less than Glasgow coma scale (GCS) After the resumption of blood flow circulation. * anaerobic unexpected (hypoxic) cerebral ischemia Encephalopathy (It should not be a hypoxic brain ischemia was induced due to heart surgery, which is scheduled) * Subjects agreed in writing that it will be participating in clinical research, as viewed from the legal representative (patient) Exclusion Criteria: * Patients who require ventilator continued * Patients who had extracorporeal membrane oxygenation(ECMO) index event occurs at the time * Patients who had a history of cardiac arrest prior to the occurrence of Index event * End-stage people of less than 12 months is expected (incurable) disease patients * Patients with cardiac arrest occurred due to brain trauma severe * Patients with damage to other organs of severe * Patients with bleeding or malignant current * Pregnant patient * Patients with central nervous system tumors undergoing radiation therapy or chemotherapy * If the patient or are participating in other clinical trials, you are planning to participate, or patients three months after the end is not passed to participate in other clinical trials